about
FES kinases are required for oncogenic FLT3 signalingReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsSurvey of activated FLT3 signaling in leukemiaSignificance of oncogenes and tumor suppressor genes in AML prognosis.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesImprovement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.Assays for pharmacodynamic analysis of histone deacetylase inhibitors.A comparison of foamy and lentiviral vector genotoxicity in SCID-repopulating cells shows foamy vectors are less prone to clonal dominance.Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell developmentRole of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.Regulation of receptor tyrosine kinase ligand processingFLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION.Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
P2860
Q24297863-850CA1D1-4191-420E-8140-B4F11B63D214Q26740953-C27D05EC-4DA2-4C91-9356-34B4D6DDF8E5Q28477934-18CE3311-E0B2-4787-8D66-352A61269002Q30250315-E396A430-4731-446D-9212-7BA25F78673CQ34158454-58A8AFD7-A567-4F74-9539-9250367C9929Q36200300-90731EFA-0068-48C6-8F1B-E4B3D3B1147FQ36408534-495342DE-A71B-4E1A-91ED-D931917F2021Q36461618-D77F68E5-5283-477A-9982-6A8948A74351Q36546255-BCD64202-ADDB-4EC0-AE37-6A94B3CED597Q37183068-15AF1476-D485-4148-A1B7-06AF57D1E7CCQ37310946-05AC2A51-7C0A-4FD1-B961-05CA0688B7EAQ37842861-77B9E45F-FCF9-4E6D-839B-ACC6DC4095FDQ38933860-C52393E1-3370-4EB7-BDDC-9C6231E20277Q41994915-8CAAC148-1605-4DFD-87AA-A256A22D64E5Q43188286-200C47C9-610B-46F8-8F27-23C1E0562A87Q46549470-64314D90-BC72-482A-A523-2DF270FBF304Q46679237-F49E9A43-02C4-46AA-8FA0-3606B09CAF4DQ49614743-F09C13E7-404B-4E6D-A306-CC928B4BEBD8
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Normal and oncogenic FLT3
@ast
Normal and oncogenic FLT3
@en
Normal and oncogenic FLT3
@nl
type
label
Normal and oncogenic FLT3
@ast
Normal and oncogenic FLT3
@en
Normal and oncogenic FLT3
@nl
prefLabel
Normal and oncogenic FLT3
@ast
Normal and oncogenic FLT3
@en
Normal and oncogenic FLT3
@nl
P3181
P1476
Normal and oncogenic FLT3
@en
P2888
P304
P3181
P356
10.1007/S00018-004-4274-X
P407
P577
2004-12-01T00:00:00Z